<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814565</url>
  </required_header>
  <id_info>
    <org_study_id>CYC-RR-001</org_study_id>
    <secondary_id>U1111-1162-4846</secondary_id>
    <nct_id>NCT02814565</nct_id>
  </id_info>
  <brief_title>Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Safety of Cyclobenzaprine HCl Extended Release (CER) 15 mg in Subjects With Acute Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl)
      extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated
      with acute painful musculoskeletal conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study was cyclobenzaprine hydrochloride (HCl) extended-release
      (CER). CER was being tested to treat participants who had muscle spasms associated with acute
      painful musculoskeletal conditions. This study looked at medication helpfulness, relief from
      muscle spasms and pain, and improvement in range of motion and daily living activities.

      The study enrolled 180 participants. Participants were randomly assigned (by chance, like
      flipping a coin) to one of the two treatment groups which remained undisclosed to the
      participant and study doctor during the study:

        -  CER 15 mg

        -  Placebo (dummy inactive pill) - this was a capsule that looks like the study drug but
           had no active ingredient

      All participants were asked to take one capsule at the same time each day throughout the
      study.

      This multi-center trial was conducted in the Russian Federation. The overall time to
      participate in this study was up to 45 days. Participants made multiple visits to the clinic,
      and were contacted by telephone after the last dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2016</start_date>
  <completion_date type="Actual">March 14, 2017</completion_date>
  <primary_completion_date type="Actual">February 10, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment</measure>
    <time_frame>Day 3</time_frame>
    <description>Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: &quot;How would you rate this study medication in improving your condition?&quot; &quot;0 = poor&quot;, &quot;1 = fair&quot;, &quot;2 = good&quot;, &quot;3 = very good&quot;, &quot;4 = excellent&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Days 7 and 14 of Treatment</measure>
    <time_frame>Days 7 and 14</time_frame>
    <description>Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: &quot;How would you rate this study medication in improving your condition?&quot; &quot;0 = poor&quot;, &quot;1 = fair&quot;, &quot;2 = good&quot;, &quot;3 = very good&quot;, &quot;4 = excellent&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment</measure>
    <time_frame>Day 3</time_frame>
    <description>The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment</measure>
    <time_frame>Days 7 and 15</time_frame>
    <description>The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Subject-Rated Global Impression on Days 3, 7, and 14 of Treatment</measure>
    <time_frame>Days 3, 7, and 14</time_frame>
    <description>Participants assessed their clinical global impression based on relief from local pain, restriction in activities of daily living, restriction of movement and intensity of local pain on a daily basis. The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders on Days 3, 7, and 14 of Treatment</measure>
    <time_frame>Days 3, 7, and 14</time_frame>
    <description>A responder was defined as a participant who had both a rating of either &quot;very good&quot; or &quot;excellent&quot; for the participant's rating of medication helpfulness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment</measure>
    <time_frame>Days 3, 7, and 15</time_frame>
    <description>The investigator assessment based on physical examination, presence of muscle spasm (presence of muscle spasm assessment). The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment</measure>
    <time_frame>Days 3, 7, and 15</time_frame>
    <description>The investigator assessed local pain based on physical examination, reaction to palpation (presence of local pain assessment). The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician Rated Assessment of Limitation of Range of Motion on Days 3, 7, and 15 of Treatment</measure>
    <time_frame>Days 3, 7, and 15</time_frame>
    <description>The investigator assessed limitation of range of motion. The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician Rated Assessment of Limitation of Activities of Daily Living on Days 3, 7, and 15 of Treatment</measure>
    <time_frame>Days 3, 7, and 15</time_frame>
    <description>The investigator assessed limitation of activities based on evaluation of the patient's reported functional assessment. The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Neck Pain</condition>
  <condition>Back Pain</condition>
  <condition>Spasm</condition>
  <arm_group>
    <arm_group_label>Cyclobenzaprine HCl 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine HCl</intervention_name>
    <description>Cyclobenzaprine HCl extended-release capsules</description>
    <arm_group_label>Cyclobenzaprine HCl 15 mg</arm_group_label>
    <other_name>Myorix®</other_name>
    <other_name>AMRIX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cyclobenzaprine HCl extended release placebo-matching capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. Signs and dates a written, informed consent form and any required privacy
             authorization prior to the initiation of any study procedures.

          3. Is experiencing for no more than 14 days cervical or lower back pain (as assessed by
             the participant) due to muscle spasms (confirmed by the physician) associated with
             acute, painful musculoskeletal conditions.

          4. Is male or female and aged 18 to 50 years, inclusive.

          5. Female participants require to be either 2 years postmenopausal or surgically sterile
             by bilateral tubal ligation, hysterectomy, or bilateral oophorectomy, or, if
             premenopausal, had to be using an approved contraceptive method.

          6. Female participants of child-bearing potential must have a negative urine human
             chorionic gonadotropin (hCG) test result for pregnancy at study entry.

          7. After signing the informed consent form, the participant agrees not to make changes to
             dietary, exercise, or smoking habits and not to enter a weight loss program during
             his/her participation in the study.

        Exclusion Criteria:

          1. Has muscular pain secondary to acute trauma or fractures (e.g., due to osteoporosis).
             Such conditions could have been ruled out based on medical history, x-ray, or physical
             examination.

          2. Has received any investigational compound within 30 days prior to Screening.

          3. If female, the participant is pregnant or lactating or intending to become pregnant
             before, during, or within 1 month after participating in this study; or intending to
             donate ova during such time period.

          4. Has a history of drug abuse or recent (within the last 12 months) history of excessive
             alcohol consumption defined as &gt;2 drinks/day (&gt;90 ml of 80 proof alcohol or
             equivalent).

          5. Has mild, moderate, severe liver impairment.

          6. Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in conduct of this study (eg, spouse,
             parent, child, sibling) or may consent under duress.

          7. Takes any concomitant medication including over-the-counter and herbal products for
             muscle spasms. If a participant is taking such medications, the medications has to be
             discontinued before starting the study.

          8. Takes or took within last 14 days medications, such as:

               1. selective serotonin reuptake inhibitors (SSRIs);

               2. serotonin norepinephrine reuptake inhibitors (SNRIs);

               3. tricyclic antidepressants (TCAs);

               4. monoamine oxidase (MAO) inhibitors;

               5. tramadol;

               6. bupropion;

               7. meperidine;

               8. verapamil;

               9. non-steroid anti-inflammatory drugs (NSAIDs);

              10. topical anti-inflammatory medications

          9. Has a history or clinical manifestations of significant medical condition, such as:

               1. hyperthyroidism;

               2. acute recovery phase of myocardial infarction;

               3. arrhythmias, heart block or conduction disturbances;

               4. congestive heart failure;

               5. angle-closure glaucoma;

               6. urinary retention;

               7. increased intraocular pressure.

         10. Has abnormal physical findings or a medical condition that might have placed the
             participant at risk or interfered with the participant's ability to participate in the
             study.

         11. Has any known condition or disorder that might have affected absorption of the study
             drug.

         12. Has a history of hypersensitivity or allergies to cyclobenzaprine and/or tricyclic
             antidepressants or any of their components.

         13. Has a history of hypersensitivity to any NSAIDs including salicylate sensitivity.

         14. Has a history of thrombocytopenia.

         15. Has a history of gastro-intestinal bleeding, cerebrovascular bleeding or other
             bleeding disorders.

         16. Had active or history of recurrent peptic ulcer/haemorrhage (two or more distinct
             episodes of proven ulceration or bleeding)

         17. Has a history of severe renal impairment

         18. Had a major surgery during the 6 months preceding study entry.

         19. Has a language barrier or any other problems precluding good communication or
             cooperation.

         20. Has any reason to believe that he/she would not be able to complete the evaluations
             needed in this study.

         21. Has a known history of positive screen for hepatitis B surface antigen, hepatitis C
             antibody, or human immunodeficiency virus (HIV) antibody.

         22. Drug abuse in anamnesis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lipetsk</city>
        <state>Lipetsk Region</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saransk</city>
        <state>Republic Of Mordovia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <state>Republic Of Tatarstan</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovsk Region</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tver</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <results_first_submitted>January 11, 2019</results_first_submitted>
  <results_first_submitted_qc>January 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2019</results_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Neck Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclobenzaprine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02814565/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02814565/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 10 investigative sites in the Russian Federation from 12 October 2016 to 14 March 2017.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of acute cervical and/or lower back pain due to muscle spasms of local origin were enrolled equally in one of two treatment groups: Cyclobenzaprine HCl 15 mg or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cyclobenzaprine HCl 15 mg</title>
          <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision, caused by AE Influenza</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
      <group_list>
        <group group_id="B1">
          <title>Cyclobenzaprine HCl 15 mg</title>
          <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" spread="9.0"/>
                    <measurement group_id="B2" value="31.5" spread="9.2"/>
                    <measurement group_id="B3" value="32.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>European (Caucasian)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.8" spread="8.2"/>
                    <measurement group_id="B2" value="169.1" spread="7.6"/>
                    <measurement group_id="B3" value="170.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.05" spread="14.53"/>
                    <measurement group_id="B2" value="66.22" spread="13.61"/>
                    <measurement group_id="B3" value="68.64" spread="14.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment</title>
        <description>Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: &quot;How would you rate this study medication in improving your condition?&quot; &quot;0 = poor&quot;, &quot;1 = fair&quot;, &quot;2 = good&quot;, &quot;3 = very good&quot;, &quot;4 = excellent&quot;.</description>
        <time_frame>Day 3</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment</title>
          <description>Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: &quot;How would you rate this study medication in improving your condition?&quot; &quot;0 = poor&quot;, &quot;1 = fair&quot;, &quot;2 = good&quot;, &quot;3 = very good&quot;, &quot;4 = excellent&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, 0=poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 1=fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2=good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 3=very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 4=excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sample Wilcoxon rank sum test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6179</p_value>
            <method>Wilcoxon Rank Sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Days 7 and 14 of Treatment</title>
        <description>Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: &quot;How would you rate this study medication in improving your condition?&quot; &quot;0 = poor&quot;, &quot;1 = fair&quot;, &quot;2 = good&quot;, &quot;3 = very good&quot;, &quot;4 = excellent&quot;.</description>
        <time_frame>Days 7 and 14</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Days 7 and 14 of Treatment</title>
          <description>Participants assessed the study medication helpfulness on a daily basis (in the daily diary), using the following 5-point rating scale: &quot;How would you rate this study medication in improving your condition?&quot; &quot;0 = poor&quot;, &quot;1 = fair&quot;, &quot;2 = good&quot;, &quot;3 = very good&quot;, &quot;4 = excellent&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7, 0=poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1=fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                    <measurement group_id="O2" value="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2=good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 3=very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4=excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 0=poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 1=fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 2=good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 3=very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4=excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7. The 2-sample Wilcoxon rank sum test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4338</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14. The 2-sample Wilcoxon rank sum test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1657</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment</title>
        <description>The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
        <time_frame>Day 3</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment</title>
          <description>The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, 1=worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 3=slight improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 4=moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 5=marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0393</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment</title>
        <description>The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
        <time_frame>Days 7 and 15</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment</title>
          <description>The investigator assessed their clinical global impression of change compared to Baseline, based on physical examination, degree of muscle spasm (presence of muscle spasm assessment), reaction to palpation (presence of local pain assessment), limitation of range of motion, and evaluation of the patient's reported functional assessment (limitation of activities of daily living assessment). The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7, 1=worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 3=slight improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4=moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 5=marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1=worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 2=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 3=slight improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 4=moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 5=marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0330</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 15. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0262</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Subject-Rated Global Impression on Days 3, 7, and 14 of Treatment</title>
        <description>Participants assessed their clinical global impression based on relief from local pain, restriction in activities of daily living, restriction of movement and intensity of local pain on a daily basis. The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
        <time_frame>Days 3, 7, and 14</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Subject-Rated Global Impression on Days 3, 7, and 14 of Treatment</title>
          <description>Participants assessed their clinical global impression based on relief from local pain, restriction in activities of daily living, restriction of movement and intensity of local pain on a daily basis. The following 5-point rating scale was used: &quot;1 = worse&quot;, &quot;2 = no change&quot;, &quot;3 = slight improvement&quot;, &quot;4 = moderate improvement&quot;, &quot;5 = marked improvement&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, 1=worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6"/>
                    <measurement group_id="O2" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 3=slight improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 4=moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 5=marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1=worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 3=slight improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4=moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 5=marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 1=worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 2=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 3=slight improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4=moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 5=marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5756</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4395</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0905</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders on Days 3, 7, and 14 of Treatment</title>
        <description>A responder was defined as a participant who had both a rating of either &quot;very good&quot; or &quot;excellent&quot; for the participant's rating of medication helpfulness.</description>
        <time_frame>Days 3, 7, and 14</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders on Days 3, 7, and 14 of Treatment</title>
          <description>A responder was defined as a participant who had both a rating of either &quot;very good&quot; or &quot;excellent&quot; for the participant's rating of medication helpfulness.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3. A two-tailed Fisher's exact test to compare the number of &quot;responders&quot; between the Placebo and the Cyclobenzaprine HCl 15 mg treatment group to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7. A two-tailed Fisher's exact test to compare the number of &quot;responders&quot; between the Placebo and the Cyclobenzaprine HCl 15 mg treatment group to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 14. A two-tailed Fisher's exact test to compare the number of &quot;responders&quot; between the Placebo and the Cyclobenzaprine HCl 15 mg treatment group to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2757</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment</title>
        <description>The investigator assessment based on physical examination, presence of muscle spasm (presence of muscle spasm assessment). The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
        <time_frame>Days 3, 7, and 15</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment</title>
          <description>The investigator assessment based on physical examination, presence of muscle spasm (presence of muscle spasm assessment). The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8"/>
                    <measurement group_id="O2" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8"/>
                    <measurement group_id="O2" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3020</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2367</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 15. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0250</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment</title>
        <description>The investigator assessed local pain based on physical examination, reaction to palpation (presence of local pain assessment). The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
        <time_frame>Days 3, 7, and 15</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment</title>
          <description>The investigator assessed local pain based on physical examination, reaction to palpation (presence of local pain assessment). The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4428</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1163</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 15. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0489</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician Rated Assessment of Limitation of Range of Motion on Days 3, 7, and 15 of Treatment</title>
        <description>The investigator assessed limitation of range of motion. The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
        <time_frame>Days 3, 7, and 15</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician Rated Assessment of Limitation of Range of Motion on Days 3, 7, and 15 of Treatment</title>
          <description>The investigator assessed limitation of range of motion. The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5275</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0880</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 15. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2542</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician Rated Assessment of Limitation of Activities of Daily Living on Days 3, 7, and 15 of Treatment</title>
        <description>The investigator assessed limitation of activities based on evaluation of the patient's reported functional assessment. The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
        <time_frame>Days 3, 7, and 15</time_frame>
        <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine HCl 15 mg</title>
            <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician Rated Assessment of Limitation of Activities of Daily Living on Days 3, 7, and 15 of Treatment</title>
          <description>The investigator assessed limitation of activities based on evaluation of the patient's reported functional assessment. The following 5-point rating scale was used: &quot;1 = none&quot;, &quot;2 = mild&quot;, &quot;3 = moderate&quot;, &quot;4 = moderately severe&quot;, &quot;5 = severe&quot;.</description>
          <population>FAS included participants who received at least one dose of investigation product, analyzed according to original treatment assignment.</population>
          <units>percentage of percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1=none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 2=mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6"/>
                    <measurement group_id="O2" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 3=moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 4=moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 5=severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6920</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0749</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 15. The 2-sample Wilcoxon sum rank test was used to test a null hypothesis of no difference between the treatment groups against a two-sided alternative hypothesis at the 0.05 level of significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2371</p_value>
            <method>Wilcoxon Sum Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug to within 30 days of last dose of study drug (Up to 45 days)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cyclobenzaprine HCl 15 mg</title>
          <description>Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version: 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Disruptive mood dysregulation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

